首页 Vascular Biogenics(usVBLT)-基本信息

Vascular Biogenics(usVBLT)-基本信息

日报更新时间:07-02 06:53

周报更新时间:01-09 11:34

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

英文名称:Vascular Biogenics


行业:医疗


简介:Vascular Biogenics Ltd.于2000年1月27日在以色列成立


电话:972-3-6346450


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 持股信息
  • 领导人信息

Vascular Biogenics是一家以色列专注于癌症治疗药物与疗法研究的生物制药公司,主要是凭借血管靶向系统平台技术(VTS)及炎症平台「Lecinoxoid」等技术,增强原始生理和遗传调节要素。 Vascular Biogenics主要候选产品是VB-111,这是一种基于基因的生物制剂,正处于治疗复发性胶质母细胞瘤(一种侵袭性脑癌)的 III 期临床试验中;以及针对复发性铂类耐药卵巢癌的 III 期临床试验,以及针对耐碘分化型甲状腺癌的 II 期临床试验。 Vascular Biogenics公司还在开发VB-111,用于治疗各种类型的晚期转移性癌症患者,包括甲状腺癌,神经内分泌癌,肾细胞癌和肺癌,目前处于 I 期临床试验阶段。 Vascular Biogenics还正在开发VB-511,一种用于肿瘤学的抗血管生成候选物。 VB-211和VB-411,是治疗外周血管疾病的促血管生成候选药物。 VB-201,一种基于类癌的化合物,用于控制慢性炎症性疾病。 VB-600,目前处于临床前阶段,用于靶向MOSPD2用于免疫肿瘤学和抗炎应用。

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Athena Capital Advisors LLC 11050 0.03% 11050 -- 2019-03-31
Ayalon Mutual Funds Ltd. 130115 0.36% 39615 43.77% 2019-07-31
RBF LLC 138919 0.39% -224805 -61.81% 2019-03-31
First Republic Inv Mgmt Inc 145000 0.40% 10000 7.41% 2019-03-31
Delaware Management Company 200000 0.56% -- -- 2019-07-31
Macquarie Group Ltd 200000 0.56% -- -- 2019-03-31
Morgan Stanley - Brokerage Accounts 277112 0.77% 45552 19.67% 2019-03-31
Sabby Management LLC 327504 0.91% -2045699 -86.20% 2019-03-31
CVI Holdings LLC 1094044 3.05% -307734 -21.95% 2019-03-31
Acadian Asset Management LLC 59427 0.17% 59427 -- 2019-03-31
Raymond James & Associates 54400 0.15% -- -- 2019-03-31
ALPS Advisors Inc 44898 0.13% -- -- 2019-07-31
Fidelity Management & Research Company 11422 0.03% -- -- 2019-07-31
Geode Capital Management, LLC 11422 0.03% -11422 -50.00% 2019-03-31
Renaissance Technologies Corp 14000 0.04% 14000 -- 2019-03-31
Group One Trading, LP 14367 0.04% -1400 -8.88% 2019-03-31
Zurcher Kantonalbank 16400 0.05% -- -- 2019-03-31
Creative Planning Inc 22000 0.06% -- -- 2019-03-31
Ladenburg Thalmann FI Services Inc 22500 0.06% -- -- 2019-03-31
Menta Capital LLC 22834 0.06% 22834 -- 2019-03-31
Spark Investment Management LLC 14200 0.04% -15060 -51.47% 2018-12-31
Vassalluzzo Scott J 19778 0.06% 19778 -- 2018-12-31
Anson Funds Management LP 45998 0.13% 45998 -- 2018-12-31
Susquehanna Financial Group, LLLP 19976 0.06% 19976 -- 2018-12-31
Susquehanna International Group, LLP 19976 0.06% 19976 -- 2018-12-31
Citadel Advisors Llc 18684 0.05% 2882 18.24% 2018-09-30
ETF Managers Group, LLC 71114 0.20% 71114 -- 2018-09-30
Virtu Financial LLC 12323 0.03% -25484 -67.41% 2018-09-30
KSM Mutual Funds Ltd 15100 0.04% -381 -2.46% 2019-02-28
Knoll Capital Management LP 896771 2.50% -- -- 2018-09-30
Amundi Pioneer Asset Management, Inc. 43100 0.12% -- -- 2018-09-30
Deutsche Bank AG 33320 0.09% 33320 -- 2018-09-30
Two Sigma Investments LLC 21900 0.06% 8500 63.43% 2018-09-30
Edmond de Rothschild Mutual Funds Manage 113100 0.32% -- -- 2018-11-30
Ladenburg Thalmann Asset Management Inc 27330 0.08% -- -- 2018-06-30
Soci¨?t¨? G¨?n¨?rale Gestion 43100 0.12% -- -- 2018-11-30
ARK Investment Management LLC 75354 0.21% -- -- 2018-11-30
Delaware Management Business Trust 200000 0.56% -- -- 2018-06-30
683 Capital Management LLC 346574 0.97% -53426 -13.36% 2018-06-30
Turner Investments LLC 41691 0.12% -- -- 2018-10-31
Franklin Advisers, Inc. 91062 0.25% -191790 -67.81% 2018-10-31
Heights Capital Management Inc 1904762 6.36% 1904762 -- 2018-06-25
Factor Advisors, LLC 60659 0.17% -- -- 2018-09-12
Empery Asset Management, LP 1904762 6.36% 1109170 139.41% 2018-06-25
Pioneer Investment Mgmt Inc 43100 0.12% 43100 -- 2018-06-30
TWO SIGMA SECURITIES, LLC 26515 0.09% 26515 -- 2018-03-31
Morgan Stanley & Co Inc 17460 0.05% 5000 40.13% 2018-06-30
Excellence Mutual Funds Ltd 12055 0.03% 8141 208.00% 2018-06-30
BOOTHBAY FUND MANAGEMENT, LLC 11263 0.04% 11263 -- 2018-03-31
Morgan Stanley Smith Barney LLC 6100 0.02% -- -- 2018-03-31
IFP Advisors, Inc 19567 0.07% 15117 339.71% 2017-12-31
J.P. Morgan Securities Inc 10500 0.04% 10500 -- 2017-12-31
Arnhold & S. Bleichroeder Advisers, LLC 120000 0.40% -154820 -56.34% 2017-12-31
Oxford Asset Management, LLC 14097 0.05% 14097 -- 2017-12-31
Van Eck Associates Corporation 2931 0.01% -3473 -54.23% 2017-12-31
Turner Investments, L.P 115300 0.43% -111011 -49.05% 2017-08-31
Burt Wealth Advisors 1674 0.01% -- -- 2017-12-31
Yelin Lapidot Mutual Funds Mgmt Ltd 3187 0.01% -- -- 2017-12-31
Tower Research Capital LLC 1781 0.01% -333 -15.75% 2017-09-30
Macquarie Investment Management Limited 330000 1.21% 330000 -- 2017-09-30
Millennium Management LLC 13565 0.05% 13565 -- 2017-09-30
Community Bank NA 1000 -- -- -- 2017-09-30
UBS Securities LLC 1000 -- -- -- 2017-09-30
Franklin Advisers Inc 452677 1.68% -456414 -50.21% 2017-06-30
Goldman, Sachs & Co. 15817 0.06% 15817 -- 2017-06-30
Metlife Securities Inc 600 -- -- -- 2016-09-30
KCG AMERICAS LLC 57817 0.22% 57817 -- 2016-09-30
Prof. Dror Harats 1586978 3.00% 7522276 0.10% 1999-11-30
Persons affiliated with Pitango Ventures 1658630 3.00% 7861906 0.10% 1999-11-30
Mr.Jecheskiel Gonczarowski 2452012 3.00% 11622537 0.10% 1999-11-30
Aurum Ventures M.K.I. Ltd 4254778 3.00% 20167648 0.20% 1999-11-30
Mr.JideJ. Zeitlin 4858737 3.00% 23030413 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
I.B.I Tracking Bluestar Israel Global -- -- -432 -100.00% 2018-12-31
Delaware Healthcare Fund 200000 0.56% -- -- 2019-06-30
Dolphin Stocks 71000 0.20% 22000 44.90% 2019-05-31
Dolphin 10/90 40000 0.11% 15000 60.00% 2019-05-31
Dolphin Flexible 19115 0.05% 2615 15.85% 2019-05-31
Fidelity 11422 0.03% -- -- 2019-06-30
KSM KTF Bluestar Israel Glob Technology -- -- -15100 -100.00% 2018-12-31
BlueStar Israel Technology ETF -- -- -47000 -100.00% 2018-12-26
SG Actions US Techno -- -- -1700 -100.00% 2018-11-30
VanEck Vectors Israel ETF -- -- -9397 -100.00% 2018-12-24
ALPS Medical Breakthroughs ETF 44898 0.13% -- -- 2018-06-14
ARK Israeli Innovation ETF -- -- -75354 -100.00% 2018-04-30
Edmond De Rothschild 90/10 $ Denominated -- -- -10000 -100.00% 2018-03-31
Edmond De Rothschild Government + 10% -- -- -20000 -100.00% 2018-03-31
EdmondDeRothschild Trckng Prtf No2 FIBI -- -- -11000 -100.00% 2018-03-31
Sela Stocks -- -- -1170 -100.00% 2018-03-31
Sela10/90 -- -- -1000 -100.00% 2018-03-31
Edmond de Rothschild Bnd Portfl +30% -- -- -42000 -100.00% 2018-03-31
Edmond de Rothschild Bond +10% -- -- -27000 -100.00% 2018-03-31
Rothschild U.S.A Taxable -- -- -1500 -100.00% 2018-03-31
Edmond De Rothschild Global Eq Portfolio -- -- -1600 -100.00% 2018-03-31
I.B.I Bluestar Israel Global Index Bskt 432 -- -- -- 2018-09-30
Edmond de Rothschild 80/20 1600 -- -- -- 2018-02-28
Franklin Biotechnology Discovery Fund 91062 0.25% -191790 -67.81% 2017-07-31
Turner Titan Long/Short Fund 41691 0.12% -- -- 2017-07-31
KSM KTF Bluestar Israel Technology 16328 0.05% 881 5.70% 2018-08-31
Yelin Lapidot 90/10 Overseas 2000 0.01% -- -- 2017-12-31
Delaware Healthcare A 200000 0.56% -- -- 2018-07-31
BlueStar TA-BIGITech 60659 0.17% -- -- 2018-09-12
Market Vectors 8271 0.02% -- -- 2018-09-14
Turner Medical Sciences Long/Short C 115300 0.43% -69320 -37.55% 2016-12-31
Turner Titan Long/Short Institutional 82661 0.31% -300 -0.36% 2016-12-31
Franklin Biotechnology Discovery A 340900 1.27% -- -- 2016-12-31
Yelin Lapidot Government + 15% 1187 -- -- -- 2015-08-31
GRT Absolute Return Fund 2000 -- 2000 -- 2015-07-31
Fidelity® NASDAQ Composite Index® Fund 6559 -- -- -- 2015-09-30

David C. Hastings David C. Hastings is Chief Financial & Accounting Officer for Arbutus Biopharma Corp. He is also on the board of SCYNEXIS, Inc., Vascular Biogenics Ltd., Entasis Therapeutics, Inc. and Entasis Therapeutics Holdings, Inc. In the past David C. Hastings held the position of Treasurer, Chief Financial & Accounting Officer of Unilife Corp., Chief Financial Officer & Treasurer of ArQule, Inc., Chief Financial Officer & Executive Vice President for Incyte Corp., Finance Director at Sunovion Pharmaceuticals, Inc., Senior Manager at PricewaterhouseCoopers LLP and Vice President & Controller at Genzyme Corp. David C. Hastings received an undergraduate degree from the University of Vermont.
Ronald Cohen Founder of Acorda Therapeutics, Inc., Ronald Cohen is a businessperson who has been at the helm of 5 different companies and currently is President, Chief Executive Officer & Director at this company and Chairman of Biotie Therapies Oyj and President, Chief Executive Officer & Director at Acorda Therapeutics Ltd. (both are subsidiaries of Acorda Therapeutics, Inc.). He is also on the board of Biotechnology Innovation Organization (former Chairman) and Vascular Biogenics Ltd. In his past career Dr. Cohen was Principal at Advanced Tissue Sciences, Inc. and Director at New York Biotechnology Association, Inc. Ronald Cohen received an undergraduate degree from Princeton University and a doctorate from Columbia University College of Physicians & Surgeons.
Bennett M. Shapiro Dr. Bennett M. Shapiro, MD, is Chairman at Vascular Biogenics Ltd. and Co-Founder at PureTech Ventures LLC. He is on the Board of Directors at PureTech Health Plc, Tal Medical, Inc., Akili Interactive Labs, Inc., Drugs for Neglected Diseases initiative, Enlight Biosciences LLC, Karuna Pharmaceuticals, Inc., The Mind & Life Institute, Vedanta Biosciences, Inc. and Dickinson College. Dr. Shapiro was previously employed as Independent Class III Director by Momenta Pharmaceuticals, Inc., EVP-Worldwide Licensing & External Research by Merck & Co., Inc., Executive Vice President-Basic Research by Merck Research Laboratories, and Professor & Chairman-Biochemistry Department by University of Washington. He also served on the board at Celera Corp., Elixir Pharmaceuticals, Inc., Celera Group, Ikaria, Inc., Protein Forest, Inc. and Satori Pharmaceuticals, Inc. He received his undergraduate degree from Dickinson College and a doctorate degree from Sidney Kimmel Medical College.
Ruth Arnon Ruth Arnon is on the board of Vascular Biogenics Ltd. and Member of Israel Academy of Sciences & Humanities and Member of European Molecular Biology Organization. She previously occupied the position of President at European Federation of Immunological Societies, Professor at Weizmann Institute of Science and General Secretary at International Union of Immunological Societies. Dr. Arnon received a graduate degree and a doctorate from The Hebrew University of Jerusalem, a doctorate from Ben-Gurion University of the Negev and a doctorate from Tel-Aviv University.
Philip Adam Serlin Currently, Philip Adam Serlin is Chief Executive Officer & Head-Investor Relations at BioLineRx Ltd. He is also on the board of Vascular Biogenics Ltd. He previously was Chief Operating & Financial Officer for Kayote Networks, Inc., Head-US Accounting Department at Deloitte & Touch Israel and Chief Financial Officer for Tescom Software Systems Testing Ltd. Mr. Serlin received an undergraduate degree from Yeshiva University and a graduate degree from George Washington University.
Ruth Arnon Ruth Arnon is on the board of Vascular Biogenics Ltd. and Member of Israel Academy of Sciences & Humanities and Member of European Molecular Biology Organization. She previously occupied the position of President at European Federation of Immunological Societies, Professor at Weizmann Institute of Science and General Secretary at International Union of Immunological Societies. Dr. Arnon received a graduate degree and a doctorate from The Hebrew University of Jerusalem, a doctorate from Ben-Gurion University of the Negev and a doctorate from Tel-Aviv University.
Amos Ron Amos Ron occupies the position of Chief Financial Officer & Secretary of Vascular Biogenics Ltd. In the past Mr. Ron occupied the position of Chief Executive & Operating Officer for Medical Compression Systems (DBN) Ltd., Chief Financial Officer for Atlantium Technologies Ltd. and Chief Financial Officer at Interpharm Laboratories Ltd. Mr. Ron received a graduate degree and an undergraduate degree from The Hebrew University of Jerusalem and an undergraduate degree from SUNY Empire State College.
Dror Harats Founder of Vascular Biogenics Ltd., Dror Harats occupies the position of Chairman of Sheba Medical Center, Chairman at Bert W. Strassburger Lipid Centre (a subsidiary of Sheba Medical Center) and Chief Executive Officer & Director at Vascular Biogenics Ltd. Dr. Harats is also Professor-Medicine at Tel-Aviv University. Dr. Harats received a doctorate from The Hebrew University Hadassah Medical School.
Eyal Breitbart Eyal Breitbart is Vice President-Research & Operations at Vascular Biogenics Ltd. Dr. Breitbart received a graduate degree, an undergraduate degree and a doctorate from Bar-Ilan University.
Naamit Sher Presently, Naamit Sher occupies the position of VP-Drug Development & Regulatory Affairs at Vascular Biogenics Ltd. In the past she was Head-QC Laboratories at Teva Pharmaceutical Industries Ltd. and Principal at Teva North America (a subsidiary of Teva Pharmaceutical Industries Ltd.) and Quality Assurance Director at Interpharm Laboratories Ltd. She received a doctorate, an undergraduate degree and a graduate degree from The Hebrew University of Jerusalem.
Ruth Alon Ruth Alon founded Israel Life Science Industry, Israel Advanced Technology Industries and Medstrada Ltd. Currently, Ms. Alon is Chairman at BrainsGate Ltd., Chief Executive Officer & Director at Medstrada Ltd. and Chairman for TransPharma Medical Ltd. Ms. Alon is also on the board of Anchiano Therapeutics Ltd., Vascular Biogenics Ltd., APOS Medical Israel Ltd. and 330 Avenue Medical Health PC. In her past career Ms. Alon was General Partner at Pitango Venture Capital, Principal at Kidder Peabody, Principal at Montgomery Securities, Inc. and Chairman of Israel Life Science Industry. Ruth Alon received an undergraduate degree from The Hebrew University of Jerusalem, an MBA from Boston University and a graduate degree from Columbia University College of Physicians & Surgeons.
Susan L. Kelley Susan L. Kelley is on the board of ArQule, Inc., Vascular Biogenics Ltd., Dar�0�1�0�8 Bioscience, Inc. and Deciphera Pharmaceuticals, Inc. In her past career she occupied the position of Executive Director-Oncology Clinical Research at Bristol-Myers Squibb World Wide Medicines Group, Vice President-Global Clinical Development at Bayer HealthCare Pharmaceuticals, Inc., Vice President-Global Clinical Development at Bayer Pharma AG, Vice President-Global Clinical Development at Bayer Schering Pharma AG, Chief Medical Officer of The Multiple Myeloma Research Foundation, Inc. and Assistant Professor at Yale School of Medicine. Dr. Kelley received an undergraduate degree from Colgate University and a doctorate from Duke University School of Medicine.
Ronald Cohen Founder of Acorda Therapeutics, Inc., Ronald Cohen is a businessperson who has been at the helm of 5 different companies and currently is President, Chief Executive Officer & Director at this company and Chairman of Biotie Therapies Oyj and President, Chief Executive Officer & Director at Acorda Therapeutics Ltd. (both are subsidiaries of Acorda Therapeutics, Inc.). He is also on the board of Biotechnology Innovation Organization (former Chairman) and Vascular Biogenics Ltd. In his past career Dr. Cohen was Principal at Advanced Tissue Sciences, Inc. and Director at New York Biotechnology Association, Inc. Ronald Cohen received an undergraduate degree from Princeton University and a doctorate from Columbia University College of Physicians & Surgeons.
Ruth Alon Ruth Alon founded Israel Life Science Industry, Israel Advanced Technology Industries and Medstrada Ltd. Currently, Ms. Alon is Chairman at BrainsGate Ltd., Chief Executive Officer & Director at Medstrada Ltd. and Chairman for TransPharma Medical Ltd. Ms. Alon is also on the board of Anchiano Therapeutics Ltd., Vascular Biogenics Ltd., APOS Medical Israel Ltd. and 330 Avenue Medical Health PC. In her past career Ms. Alon was General Partner at Pitango Venture Capital, Principal at Kidder Peabody, Principal at Montgomery Securities, Inc. and Chairman of Israel Life Science Industry. Ruth Alon received an undergraduate degree from The Hebrew University of Jerusalem, an MBA from Boston University and a graduate degree from Columbia University College of Physicians & Surgeons.
Erez Feige Erez Feige occupies the position of Vice President-Business Operations at Vascular Biogenics Ltd. Dr. Feige received a doctorate and an undergraduate degree from Bar-Ilan University.
Ayelet Horn Ayelet Horn occupies the position of General Counsel for Vascular Biogenics Ltd. Ms. Horn received a graduate degree from Tel-Aviv University and an MBA from Heriot-Watt University.
Shmuel Ben Zvi Shmuel Ben Zvi is on the board of Bank Leumi Le-Israel Ltd., Sol-Gel Technologies Ltd. and Vascular Biogenics Ltd. and Manager & Owner at Shmuel (Muli) Ben Zvi Ltd. In the past he occupied the position of Deputy Chief Executive Officer at Teva Pharmaceutical Industries Ltd. He received an undergraduate degree, a doctorate and a graduate degree from Tel-Aviv University.
Tami Rachmilewitz Tami Rachmilewitz holds the position of Vice President-Clinical Development at Vascular Biogenics Ltd.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐